Promising results were noted in Phase 1b of the TROPION-Lung04 trial, combining Datopotamab Deruxtecan and Durvalumab for Non-Small Cell Lung Cancer

Preliminary findings from the TROPION-Lung04 Phase 1b study indicated that when datopotamab deruxtecan (Dato-DXd) is used alongside Durvalumab, an anti-PD-L1 treatment, with or without Carboplatin, it showed promising outcomes and no new safety signals in patients who have not been treated before for advanced or metastatic non-small cell lung cancer. The findings were shared during a last-minute oral discourse at the IASLC 2023 World Convention on Lung Cancer.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Datopotamab deruxtecan, a specifically designed TROP2 targeted DXd antibody drug conjugate, is a collaborative development by Daiichi Sankyo and AstraZeneca.

Each year, advanced NSCLC is diagnosed in over a million people globally. First-line therapy with immune checkpoint inhibitors, with or without chemotherapy, has improved patient outcomes who do not possess actionable genomic alterations like EGFR or ALK. Nonetheless, disease progression is an eventual reality for most patients. The protein TROP2 is found in large numbers of NSCLC tumors. As of now, TROP2 targeted ADCs are not approved for the treatment of lung cancer patients.

“For most advanced non-small cell lung cancer patients, initial treatment is followed by disease progression, indicating the need for better first-line treatment options”, stated Saiama Waqar, MD, from Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. “We look forward to the phase 3 program evaluating various datopotamab deruxtecan and immune checkpoint inhibitor combinations in this context.”

Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo, commented on the early trial results,“We are excited to continue this TROP2 targeted antibody drug conjugate evaluation in multiple ongoing phase 3 trials addressing the long-standing need of lung cancer community across multiple treatment settings.”

“The initial TROPION-Lung04 results in the first-line setting have reinforced our faith in datopotamab deruxtecan as a possible treatment option for advanced non-small cell lung cancer patients,” shared Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, “With our extensive clinical program, we look forward to evaluating this TROP2 targeted ADC in lung cancer across different treatment settings, alone and in novel combinations”. 

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 14, 2023, there are 8 investigational drugs for the TOP1 and Trop-2 target, including 38 applicable indications,24 R&D institutions involved, with related clinical trials reaching 120，and as many as 133 patents.

In NSCLC, the TROPION-Lung07, TROPION-Lung08 and AVANZAR phase 3 trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations as potential first-line treatment options for patients with advanced or metastatic disease, a strategy informed by the results of two early trials. AstraZeneca is also researching a potential diagnostic test to help identify patients most likely to benefit from treatment with datopotamab deruxtecan.